EUROPEAN-DATAWAREHOUSE
30.6.2022 08:02:08 CEST | Business Wire | Press release
Today marks the 10th anniversary of European DataWarehouse (EDW), Europe’s first securitisation repository, established in 2012 as part of the European Central Bank’s ABS Loan-Level Initiative.
In its first decade of operating as a market infrastructure, EDW has strengthened its position as Europe’s first securitisation repository through its registration by both the European Securities and Markets Authority (ESMA) and the Financial Conduct Authority (FCA).
Since 2012, EDW has not only facilitated the centralisation, transparency, and standardisation of European loan-level data for the securitisation market, but has also contributed to countless consultations and regulatory initiatives that have shaped the disclosure frameworks in both the EU and UK financial markets.
Reflecting on 10 years of progress, Dr. Christian Thun, CEO of EDW said, “EDW’s success has been achieved through the hard work and dedication of our team members and the continuous optimisation of our reporting solutions to meet ever-changing market needs. I take great pride in what we have accomplished over the last decade, and I want to thank all those who have accompanied us on our journey thus far.”
EDW Chairman, Prof. José Manuel González-Páramo, continued, “As we celebrate this important milestone, I am even more enthusiastic about the many opportunities we have to contribute to the future and evolution of Europe’s securitisation market.”
“As a founding EDW shareholder who worked closely with the ECB in establishing EDW in 2012 as a centralised repository, I speak on behalf of the market in congratulating EDW on its role in helping to restore a safe European securitisation market,” said Steve Gandy, former Managing Director and Head of Private Debt Mobilisation, Notes & Structuring at Santander Corporate & Investment Banking.
EDW is funded and owned by 16 leading market participants including banks, rating agencies and professional organisations. In 2018, European DataWarehouse Limited was established in the United Kingdom and operates as a 100% subsidiary of its parent company, European DataWarehouse GmbH.
About European DataWarehouse
European DataWarehouse (EDW) is a Securitisation Repository designated by both the European Securities and Markets Authority and the Financial Conduct Authority. It was established in 2012 as the first Securitisation Repository in Europe to facilitate the collection, validation, and dissemination of standardised loan-level data for Asset-Backed Securities and private whole loan portfolios.
EDW stores loan-level data and corresponding documentation for investors and other market participants. Operating as a market infrastructure, EDW aims to increase transparency and restore confidence in the ABS market. Through EDW's data, users can analyse underlying portfolios in a more efficient way and compare portfolios on a systematic basis.
For the latest updates from European DataWarehouse, follow us on LinkedIn or visit our websites www.eurodw.eu / www.eurodw.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom